Conrig Pharma identifies and develops new innovative drugs in new indications and markets. 

Conrig Pharma uses molecular modifications in order to improve ADME/pharmacokinetic properties and generate new IPR. The strategy will provide long exclusivity through a cost effective and de-risked development.

Conrig Pharma operates in a cost efficient manner, with minimal infrastructure, through a team of experienced advisors and CROs. 

Conrig Pharma projects:

ST-015 is ready to clinical proof of concept studies in 2018. Strong pre-clinical and clinical evidence supports that ST-015 will be effective in treatment of chronic cough associated with serious respiratory disorders. ST-015 will provide acute symptomatic relief and disease modification after subchronic administration. Initial focus will be treatment of Idiopathic Pulmonary Fibrosis.   


Current treatment options of cough:  OTC remedies incl. cough syrups, as well as dextromethorphan, codein etc. None of these are really efficacious and contrary might induce some safety concerns. Thus, there is a significant unmet need and treatment potential for new drug candidates.